|
Brief Communication  Open Access
|
| |
|
| |
Allergy Asthma Immunol Res. 2013 Oct;5:e202. English.
Published online 2013 October 08. |
| Copyright © 2013 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease |
| |
| Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: A Preliminary Report |
Dong-Ho Nahm, 1 Su-Mi Cho,1 Myoung-Eun Kim,1 Yeo-Jin Kim,1 and Sook-Yeong Jeon2 |
| 1Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea. |
| 2Yonsei-Ajou Pediatric Clinic, Gwang-Ju, Korea. |
Correspondence to: Dong-Ho Nahm, MD, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon 443-721, Korea. Tel: +82-31-219-5152; Fax: +82-31-219-5154; Email: dhnahm@gmail.com
|
|
Received May 28, 2013; Accepted June 19, 2013.
|
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
|
Abstract
|
The management of severe recalcitrant atopic dermatitis (AD) is a challenging issue for clinicians and patients. We hypothesized that repeated intramuscular injections of autologous immunoglobulin (autologous immunoglobulin therapy: AIGT) might induce clinical improvements in patients with AD by stimulation of the active immune response to antigen-binding-site of pathogenic antibodies. We tried AIGT in 3 adult patients with severe recalcitrant AD whose clinical conditions could not be effectively controlled by medical treatments (including oral cyclosporine) for more than 2 years. Autologous immunoglobulin was purified from the autologous plasma by affinity chromatography using Protein A. The patients were treated by an intramuscular injection of 50 mg of autologous immunoglobulin twice a week for 4 weeks. A clinical severity score of AD (SCORAD value) showed a decrease greater than 30% at 8 weeks after the initiation of AIGT compared with the baseline before the initiation of AIGT in all 3 patients with severe recalcitrant AD. No significant side effects from treatment were observed. Further studies with larger numbers of patients are required to evaluate the clinical usefulness of AIGT for AD.
|
| |
Keywords: Dermatitis, atopic, immunoglobulin, treatment.
|
|
|
|
|
Article
Download Citation
E-mail
Twitter
Facebook
No comments:
Post a Comment